Cardiovascular safety of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study

OBJECTIVE: This analysis was conducted to investigate the cardiovascular (CV) safety outcomes from the MILAI II study. MILAI II was conducted to evaluate the long‐term safety and efficacy of antimuscarinic add‐on therapy to mirabegron over 52 weeks in patients with overactive bladder (OAB) symptoms....

Descripción completa

Detalles Bibliográficos
Autores principales: Katoh, Takao, Igawa, Yasuhiko, Yamaguchi, Osamu, Kato, Daisuke, Hamada, Takuya, Kuroishi, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Asia Pty Ltd 2019
Materias:
Original Articles ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004007/
https://www.ncbi.nlm.nih.gov/pubmed/31571403
http://dx.doi.org/10.1111/luts.12286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004007/
https://www.ncbi.nlm.nih.gov/pubmed/31571403
http://dx.doi.org/10.1111/luts.12286

Ejemplares similares